What is Andromeda?
Andromeda operates at the intersection of advanced robotics and human-centric care. Its core product, Abi, is a sophisticated robotic companion designed to foster meaningful connections while simultaneously enhancing the operational capacity of professional care teams. By integrating artificial intelligence with empathetic design, Andromeda addresses the critical labor shortages and emotional support gaps currently facing the healthcare and aged-care sectors. The company's market position is defined by its commitment to human-robot interaction, aiming to transform how care is delivered in both residential and clinical environments. Through its focus on scalable, high-impact robotics, Andromeda is carving out a niche as a leader in the burgeoning field of assistive technology.
How much funding has Andromeda raised?
Andromeda has raised a total of $28.9M across 2 funding rounds:
Series A
$14.8M
Private Equity
$14.1M
Series A (2025): $14.8M with participation from Artesian, Forerunner Ventures, Rethink Impact, and Main Sequence Ventures
Private Equity (2025): $14.1M, investors not publicly disclosed
Key Investors in Andromeda
Artesian
Artesian is a global alternative investment management firm specializing in public and private debt, venture capital, and impact investment strategies.
Forerunner Ventures
Forerunner Ventures partners with founders to build category-defining companies at the intersection of technology and human behavior, focusing on emerging consumer demands.
Rethink Impact
Rethink Impact is a venture capital firm that invests in entrepreneurs and technology platforms focused on creating ecosystems of change across healthcare and social sectors.
What's next for Andromeda?
With the successful closure of this major strategic investment, Andromeda is poised to enter a period of rapid expansion. The company's strategic focus will likely shift toward scaling its manufacturing capabilities and expanding its market reach beyond Australia. Furthermore, the integration of advanced machine learning models into the Abi platform will be a priority, ensuring that the robotic companion remains at the forefront of care-tech innovation. As the company navigates this growth phase, it will continue to leverage its partnerships with key venture capital firms to refine its business model and address the evolving demands of the global healthcare market. The focus remains on achieving long-term sustainability while maintaining the high standards of care that define the Andromeda brand.
See full Andromeda company page
